Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2006

Open Access 01-12-2006 | Review

Epigenetic aberrations and cancer

Authors: Miryam Ducasse, Mark A Brown

Published in: Molecular Cancer | Issue 1/2006

Login to get access

Abstract

The correlation between epigenetic aberrations and disease underscores the importance of epigenetic mechanisms. Here, we review recent findings regarding chromatin modifications and their relevance to cancer.
Literature
1.
Sims RJ, Reinberg D: From chromatin to cancer: a new histone lysine methyltransferase enters the mix. Nat Cell Biol. 2004, 6 (8): 685-687. 10.1038/ncb0804-685PubMed
2.
Cavalli G: Chromatin and epigenetics in development: blending cellular memory with cell fate plasticity. Development. 2006, 133 (11): 2089-2094. 10.1242/dev.02402PubMed
3.
Brown MA, Sims RJ, Gottlieb PD, Tucker PW: Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol Cancer. 2006, 5: 26- 10.1186/1476-4598-5-26PubMedCentralPubMed
4.
Jenuwein T, Allis CD: Translating the histone code. Science. 2001, 293 (5532): 1074-1080. 10.1126/science.1063127PubMed
5.
Jenuwein T: The epigenetic magic of histone lysine methylation. Febs J. 2006, 273 (14): 3121-3135. 10.1111/j.1742-4658.2006.05343.xPubMed
6.
Festenstein R, Aragon L: Decoding the epigenetic effects of chromatin. Genome Biol. 2003, 4 (10): 342- 10.1186/gb-2003-4-10-342PubMedCentralPubMed
7.
Mito Y, Henikoff JG, Henikoff S: Genome-scale profiling of histone H3.3 replacement patterns. Nat Genet. 2005, 37 (10): 1090-1097. 10.1038/ng1637PubMed
8.
9.
Staub E, Grone J, Mennerich D, Ropcke S, Klamann I, Hinzmann B, Castanos-Velez E, Mann B, Pilarsky C, Brummendorf T, Weber B, Buhr HJ, Rosenthal A: A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer. Mol Cancer. 2006, 5: 37- 10.1186/1476-4598-5-37PubMedCentralPubMed
10.
Baylin SB, Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer. 2006, 6 (2): 107-116. 10.1038/nrc1799PubMed
11.
Turner BM: Cellular memory and the histone code. Cell. 2002, 111 (3): 285-291. 10.1016/S0092-8674(02)01080-2PubMed
12.
Richmond TJ: Genomics: predictable packaging. Nature. 2006, 442 (7104): 750-752. 10.1038/442750aPubMed
13.
Kornberg RD, Lorch Y: Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell. 1999, 98 (3): 285-294. 10.1016/S0092-8674(00)81958-3PubMed
14.
Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ: Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature. 1997, 389 (6648): 251-260. 10.1038/38444PubMed
15.
Yap KL, Zhou MM: Structure and function of protein modules in chromatin biology. Results Probl Cell Differ. 2006, 41: 1-23.PubMed
16.
Khorasanizadeh S: The nucleosome: from genomic organization to genomic regulation. Cell. 2004, 116 (2): 259-272. 10.1016/S0092-8674(04)00044-3PubMed
17.
Hayes JJ, Clark DJ, Wolffe AP: Histone contributions to the structure of DNA in the nucleosome. Proc Natl Acad Sci U S A. 1991, 88 (15): 6829-6833. 10.1073/pnas.88.15.6829PubMedCentralPubMed
18.
Vitolo JM, Thiriet C, Hayes JJ: The H3-H4 N-terminal tail domains are the primary mediators of transcription factor IIIA access to 5S DNA within a nucleosome. Mol Cell Biol. 2000, 20 (6): 2167-2175. 10.1128/MCB.20.6.2167-2175.2000PubMedCentralPubMed
19.
Davey CA, Sargent DF, Luger K, Maeder AW, Richmond TJ: Solvent mediated interactions in the structure of the nucleosome core particle at 1.9 a resolution. J Mol Biol. 2002, 319 (5): 1097-1113. 10.1016/S0022-2836(02)00386-8PubMed
20.
Segal E, Fondufe-Mittendorf Y, Chen L, Thastrom A, Field Y, Moore IK, Wang JP, Widom J: A genomic code for nucleosome positioning. Nature. 2006, 442 (7104): 772-778. 10.1038/nature04979PubMedCentralPubMed
21.
Vicent GP, Nacht AS, Smith CL, Peterson CL, Dimitrov S, Beato M: DNA instructed displacement of histones H2A and H2B at an inducible promoter. Mol Cell. 2004, 16 (3): 439-452. 10.1016/j.molcel.2004.10.025PubMed
22.
Oudet P, Gross-Bellard M, Chambon P: Electron microscopic and biochemical evidence that chromatin structure is a repeating unit. Cell. 1975, 4 (4): 281-300. 10.1016/0092-8674(75)90149-XPubMed
23.
Schalch T, Duda S, Sargent DF, Richmond TJ: X-ray structure of a tetranucleosome and its implications for the chromatin fibre. Nature. 2005, 436 (7047): 138-141. 10.1038/nature03686PubMed
24.
Bharath MM, Chandra NR, Rao MR: Molecular modeling of the chromatosome particle. Nucleic Acids Res. 2003, 31 (14): 4264-4274. 10.1093/nar/gkg481PubMedCentralPubMed
25.
Bednar J, Horowitz RA, Grigoryev SA, Carruthers LM, Hansen JC, Koster AJ, Woodcock CL: Nucleosomes, linker DNA, and linker histone form a unique structural motif that directs the higher-order folding and compaction of chromatin. Proc Natl Acad Sci U S A. 1998, 95 (24): 14173-14178. 10.1073/pnas.95.24.14173PubMedCentralPubMed
26.
Cui Y, Bustamante C: Pulling a single chromatin fiber reveals the forces that maintain its higher-order structure. Proc Natl Acad Sci U S A. 2000, 97 (1): 127-132. 10.1073/pnas.97.1.127PubMedCentralPubMed
27.
Robinson PJ, Rhodes D: Structure of the '30 nm' chromatin fibre: a key role for the linker histone. Curr Opin Struct Biol. 2006, 16 (3): 336-343. 10.1016/j.sbi.2006.05.007PubMed
28.
Adkins NL, Watts M, Georgel PT: To the 30-nm chromatin fiber and beyond. Biochim Biophys Acta. 2004, 1677 (1-3): 12-23.PubMed
29.
McBryant SJ, Adams VH, Hansen JC: Chromatin architectural proteins. Chromosome Res. 2006, 14 (1): 39-51. 10.1007/s10577-006-1025-xPubMed
30.
Reiner SL: Epigenetic control in the immune response. Hum Mol Genet. 2005, 14 Spec No 1: R41-6. 10.1093/hmg/ddi115PubMed
31.
Margueron R, Trojer P, Reinberg D: The key to development: interpreting the histone code?. Curr Opin Genet Dev. 2005, 15 (2): 163-176. 10.1016/j.gde.2005.01.005PubMed
32.
Lin W, Dent SY: Functions of histone-modifying enzymes in development. Curr Opin Genet Dev. 2006, 16 (2): 137-142. 10.1016/j.gde.2006.02.002PubMed
33.
Dannenberg JH, David G, Zhong S, van der Torre J, Wong WH, Depinho RA: mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival. Genes Dev. 2005, 19 (13): 1581-1595. 10.1101/gad.1286905PubMedCentralPubMed
34.
Zhang Y, Reinberg D: Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. 2001, 15 (18): 2343-2360. 10.1101/gad.927301PubMed
35.
Lachner M, Jenuwein T: The many faces of histone lysine methylation. Curr Opin Cell Biol. 2002, 14 (3): 286-298. 10.1016/S0955-0674(02)00335-6PubMed
36.
Kouzarides T: Histone methylation in transcriptional control. Curr Opin Genet Dev. 2002, 12 (2): 198-209. 10.1016/S0959-437X(02)00287-3PubMed
37.
Bernstein E, Hake SB: The nucleosome: a little variation goes a long way. Biochem Cell Biol. 2006, 84 (4): 505-517. 10.1139/O06-085PubMed
38.
Lund AH, van Lohuizen M: Epigenetics and cancer. Genes Dev. 2004, 18 (19): 2315-2335. 10.1101/gad.1232504PubMed
39.
Fraga MF, Esteller M: Towards the human cancer epigenome: a first draft of histone modifications. Cell Cycle. 2005, 4 (10): 1377-1381.PubMed
40.
Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, Fraga MF, Herranz M, Paz MF, Sanchez-Cespedes M, Artiga MJ, Guerrero D, Castells A, von Kobbe C, Bohr VA, Esteller M: Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci U S A. 2006, 103 (23): 8822-8827. 10.1073/pnas.0600645103PubMedCentralPubMed
41.
Egger G, Liang G, Aparicio A, Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004, 429 (6990): 457-463. 10.1038/nature02625PubMed
42.
Dhillon N, Kamakaka RT: Breaking through to the other side: silencers and barriers. Curr Opin Genet Dev. 2002, 12 (2): 188-192. 10.1016/S0959-437X(02)00285-XPubMed
43.
Wittenberg C, Reed SI: Cell cycle-dependent transcription in yeast: promoters, transcription factors, and transcriptomes. Oncogene. 2005, 24 (17): 2746-2755. 10.1038/sj.onc.1208606PubMed
44.
Ney PA: Gene expression during terminal erythroid differentiation. Curr Opin Hematol. 2006, 13 (4): 203-208. 10.1097/01.moh.0000231415.18333.2cPubMed
45.
Teng CT: Factors regulating lactoferrin gene expression. Biochem Cell Biol. 2006, 84 (3): 263-267. 10.1139/O06-034PubMed
46.
Olson EN: Gene regulatory networks in the evolution and development of the heart. Science. 2006, 313 (5795): 1922-1927. 10.1126/science.1132292PubMedCentralPubMed
47.
Thomas MC, Chiang CM: The general transcription machinery and general cofactors. Crit Rev Biochem Mol Biol. 2006, 41 (3): 105-178. 10.1080/10409230600648736PubMed
48.
Hebbar PB, Archer TK: Chromatin remodeling by nuclear receptors. Chromosoma. 2003, 111 (8): 495-504.PubMed
49.
Kumar R, Johnson BH, Thompson EB: Overview of the structural basis for transcription regulation by nuclear hormone receptors. Essays Biochem. 2004, 40: 27-39.PubMed
50.
Hawkins RD, Ren B: Genome-wide location analysis: insights on transcriptional regulation. Hum Mol Genet. 2006, 15 Spec No 1: R1-7. 10.1093/hmg/ddl043PubMed
51.
Johnson CN, Adkins NL, Georgel P: Chromatin remodeling complexes: ATP-dependent machines in action. Biochem Cell Biol. 2005, 83 (4): 405-417. 10.1139/o05-115PubMed
52.
Becker PB, Hörz W: ATP-dependent nucleosome remodeling. Annu Rev Biochem. 2002, 71: 247-273. 10.1146/annurev.biochem.71.110601.135400PubMed
53.
Horn PJ, Peterson CL: The bromodomain: a regulator of ATP-dependent chromatin remodeling?. Front Biosci. 2001, 6: D1019-23.PubMed
54.
Dirscherl SS, Krebs JE: Functional diversity of ISWI complexes. Biochem Cell Biol. 2004, 82 (4): 482-489. 10.1139/o04-044PubMed
55.
Bouazoune K, Mitterweger A, Langst G, Imhof A, Akhtar A, Becker PB, Brehm A: The dMi-2 chromodomains are DNA binding modules important for ATP-dependent nucleosome mobilization. Embo J. 2002, 21 (10): 2430-2440. 10.1093/emboj/21.10.2430PubMedCentralPubMed
56.
Nagaich AK, Walker DA, Wolford R, Hager GL: Rapid periodic binding and displacement of the glucocorticoid receptor during chromatin remodeling. Mol Cell. 2004, 14 (2): 163-174. 10.1016/S1097-2765(04)00178-9PubMed
57.
Mellor J: The dynamics of chromatin remodeling at promoters. Mol Cell. 2005, 19 (2): 147-157. 10.1016/j.molcel.2005.06.023PubMed
58.
Chen T, Li E: Establishment and maintenance of DNA methylation patterns in mammals. Curr Top Microbiol Immunol. 2006, 301: 179-201.PubMed
59.
Wade PA: Methyl CpG binding proteins: coupling chromatin architecture to gene regulation. Oncogene. 2001, 20 (24): 3166-3173. 10.1038/sj.onc.1204340PubMed
60.
Villagra A, Gutierrez J, Paredes R, Sierra J, Puchi M, Imschenetzky M, Wijnen Av A, Lian J, Stein G, Stein J, Montecino M: Reduced CpG methylation is associated with transcriptional activation of the bone-specific rat osteocalcin gene in osteoblasts. J Cell Biochem. 2002, 85 (1): 112-122. 10.1002/jcb.10113PubMed
61.
Monk M: Epigenetic programming of differential gene expression in development and evolution. Dev Genet. 1995, 17 (3): 188-197. 10.1002/dvg.1020170303PubMed
62.
Bird A: DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16 (1): 6-21. 10.1101/gad.947102PubMed
63.
Hendrich B, Tweedie S: The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet. 2003, 19 (5): 269-277. 10.1016/S0168-9525(03)00080-5PubMed
64.
Li E: Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet. 2002, 3 (9): 662-673. 10.1038/nrg887PubMed
65.
Holmes R, Soloway PD: Regulation of imprinted DNA methylation. Cytogenet Genome Res. 2006, 113 (1-4): 122-129. 10.1159/000090823PubMed
66.
Strahl BD, Allis CD: The language of covalent histone modifications. Nature. 2000, 403 (6765): 41-45. 10.1038/47412PubMed
67.
Dutnall RN, Denu JM: Methyl magic and HAT tricks. Nat Struct Biol. 2002, 9 (12): 888-891. 10.1038/nsb1202-888PubMed
68.
McManus KJ, Hendzel MJ: The relationship between histone H3 phosphorylation and acetylation throughout the mammalian cell cycle. Biochem Cell Biol. 2006, 84 (4): 640-657. 10.1139/O06-086PubMed
69.
Daujat S, Bauer UM, Shah V, Turner B, Berger S, Kouzarides T: Crosstalk between CARM1 methylation and CBP acetylation on histone H3. Curr Biol. 2002, 12 (24): 2090-2097. 10.1016/S0960-9822(02)01387-8PubMed
70.
Dillon N, Festenstein R: Unravelling heterochromatin: competition between positive and negative factors regulates accessibility. Trends Genet. 2002, 18 (5): 252-258. 10.1016/S0168-9525(02)02648-3PubMed
71.
Allfrey VG, Faulkner R, Mirsky AE: Acetylation and Methylation of Histones and Their Possible Role in the Regulation of Rna Synthesis. Proc Natl Acad Sci U S A. 1964, 51: 786-794. 10.1073/pnas.51.5.786PubMedCentralPubMed
72.
Kimura A, Matsubara K, Horikoshi M: A decade of histone acetylation: marking eukaryotic chromosomes with specific codes. J Biochem (Tokyo). 2005, 138 (6): 647-662.
73.
Verdone L, Caserta M, Di Mauro E: Role of histone acetylation in the control of gene expression. Biochem Cell Biol. 2005, 83 (3): 344-353. 10.1139/o05-041PubMed
74.
Verdone L, Agricola E, Caserta M, Di Mauro E: Histone acetylation in gene regulation. Brief Funct Genomic Proteomic. 2006, 5 (3): 209-221. 10.1093/bfgp/ell028PubMed
75.
Umlauf D, Goto Y, Feil R: Site-specific analysis of histone methylation and acetylation. Methods Mol Biol. 2004, 287: 99-120.PubMed
76.
de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003, 370 (Pt 3): 737-749. 10.1042/BJ20021321PubMedCentralPubMed
77.
Agalioti T, Chen G, Thanos D: Deciphering the transcriptional histone acetylation code for a human gene. Cell. 2002, 111 (3): 381-392. 10.1016/S0092-8674(02)01077-2PubMed
78.
Xu F, Zhang K, Grunstein M: Acetylation in histone H3 globular domain regulates gene expression in yeast. Cell. 2005, 121 (3): 375-385. 10.1016/j.cell.2005.03.011PubMed
79.
Brownell JE, Zhou J, Ranalli T, Kobayashi R, Edmondson DG, Roth SY, Allis CD: Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell. 1996, 84 (6): 843-851. 10.1016/S0092-8674(00)81063-6PubMed
80.
Yang XJ: The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res. 2004, 32 (3): 959-976. 10.1093/nar/gkh252PubMedCentralPubMed
81.
Gregoretti IV, Lee YM, Goodson HV: Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004, 338 (1): 17-31. 10.1016/j.jmb.2004.02.006PubMed
82.
Marmorstein R, Roth SY: Histone acetyltransferases: function, structure, and catalysis. Curr Opin Genet Dev. 2001, 11 (2): 155-161. 10.1016/S0959-437X(00)00173-8PubMed
83.
Taunton J, Hassig CA, Schreiber SL: A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science. 1996, 272 (5260): 408-411. 10.1126/science.272.5260.408PubMed
84.
Blander G, Guarente L: The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004, 73: 417-435. 10.1146/annurev.biochem.73.011303.073651PubMed
85.
Nusinzon I, Horvath CM: Histone deacetylases as transcriptional activators? Role reversal in inducible gene regulation. Sci STKE. 2005, 2005 (296): re11- 10.1126/stke.2962005re11PubMed
86.
Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P, Zhang Y: Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006, 439 (7078): 811-816. 10.1038/nature04433PubMed
87.
Wang H, An W, Cao R, Xia L, Erdjument-Bromage H, Chatton B, Tempst P, Roeder RG, Zhang Y: mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Mol Cell. 2003, 12 (2): 475-487. 10.1016/j.molcel.2003.08.007PubMed
88.
Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, Emre NC, Schreiber SL, Mellor J, Kouzarides T: Active genes are tri-methylated at K4 of histone H3. Nature. 2002, 419 (6905): 407-411. 10.1038/nature01080PubMed
89.
O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA, Jenuwein T: The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol. 2001, 21 (13): 4330-4336. 10.1128/MCB.21.13.4330-4336.2001PubMedCentralPubMed
90.
Sims RJ, Nishioka K, Reinberg D: Histone lysine methylation: a signature for chromatin function. Trends Genet. 2003, 19 (11): 629-639. 10.1016/j.tig.2003.09.007PubMed
91.
Sims RJ, Chen CF, Santos-Rosa H, Kouzarides T, Patel SS, Reinberg D: Human but not yeast CHD1 binds directly and selectively to histone H3 methylated at lysine 4 via its tandem chromodomains. J Biol Chem. 2005, 280 (51): 41789-41792. 10.1074/jbc.C500395200PubMedCentralPubMed
92.
Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y: Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004, 119 (7): 941-953. 10.1016/j.cell.2004.12.012PubMed
93.
Ahmad K, Henikoff S: The histone variant H3.3 marks active chromatin by replication-independent nucleosome assembly. Mol Cell. 2002, 9 (6): 1191-1200. 10.1016/S1097-2765(02)00542-7PubMed
94.
Meneghini MD, Wu M, Madhani HD: Conserved histone variant H2A.Z protects euchromatin from the ectopic spread of silent heterochromatin. Cell. 2003, 112 (5): 725-736. 10.1016/S0092-8674(03)00123-5PubMed
95.
Chakravarthy S, Gundimella SK, Caron C, Perche PY, Pehrson JR, Khochbin S, Luger K: Structural characterization of the histone variant macroH2A. Mol Cell Biol. 2005, 25 (17): 7616-7624. 10.1128/MCB.25.17.7616-7624.2005PubMedCentralPubMed
96.
Regnier V, Vagnarelli P, Fukagawa T, Zerjal T, Burns E, Trouche D, Earnshaw W, Brown W: CENP-A is required for accurate chromosome segregation and sustained kinetochore association of BubR1. Mol Cell Biol. 2005, 25 (10): 3967-3981. 10.1128/MCB.25.10.3967-3981.2005PubMedCentralPubMed
97.
Mattick JS, Makunin IV: Non-coding RNA. Hum Mol Genet. 2006, 15 Spec No 1: R17-29. 10.1093/hmg/ddl046PubMed
98.
Kawasaki H, Taira K: Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature. 2004, 431 (7005): 211-217. 10.1038/nature02889PubMed
99.
Morris KV, Chan SW, Jacobsen SE, Looney DJ: Small interfering RNA-induced transcriptional gene silencing in human cells. Science. 2004, 305 (5688): 1289-1292. 10.1126/science.1101372PubMed
100.
Singh U, Fohn LE, Wakayama T, Ohgane J, Steinhoff C, Lipkowitz B, Schulz R, Orth A, Ropers HH, Behringer RR, Tanaka S, Shiota K, Yanagimachi R, Nuber UA, Fundele R: Different molecular mechanisms underlie placental overgrowth phenotypes caused by interspecies hybridization, cloning, and Esx1 mutation. Dev Dyn. 2004, 230 (1): 149-164. 10.1002/dvdy.20024PubMed
101.
Kavi HH, Fernandez HR, Xie W, Birchler JA: RNA silencing in Drosophila. FEBS Lett. 2005, 579 (26): 5940-5949. 10.1016/j.febslet.2005.08.069PubMed
102.
Bernstein E, Allis CD: RNA meets chromatin. Genes Dev. 2005, 19 (14): 1635-1655. 10.1101/gad.1324305PubMed
103.
Santos-Reboucas CB, Pimentel MM: Implication of abnormal epigenetic patterns for human diseases. Eur J Hum Genet. 2006.
104.
Sansam CG, Roberts CW: Epigenetics and cancer: altered chromatin remodeling via Snf5 loss leads to aberrant cell cycle regulation. Cell Cycle. 2006, 5 (6): 621-624.PubMed
105.
Dennis K, Fan T, Geiman T, Yan Q, Muegge K: Lsh, a member of the SNF2 family, is required for genome-wide methylation. Genes Dev. 2001, 15 (22): 2940-2944. 10.1101/gad.929101PubMedCentralPubMed
106.
Santoro R, Li J, Grummt I: The nucleolar remodeling complex NoRC mediates heterochromatin formation and silencing of ribosomal gene transcription. Nat Genet. 2002, 32 (3): 393-396. 10.1038/ng1010PubMed
107.
Gibbons RJ, McDowell TL, Raman S, O'Rourke DM, Garrick D, Ayyub H, Higgs DR: Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. Nat Genet. 2000, 24 (4): 368-371. 10.1038/74191PubMed
108.
Yamamichi N, Yamamichi-Nishina M, Mizutani T, Watanabe H, Minoguchi S, Kobayashi N, Kimura S, Ito T, Yahagi N, Ichinose M, Omata M, Iba H: The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene. 2005, 24 (35): 5471-5481. 10.1038/sj.onc.1208716PubMed
109.
Debauve G, Nonclercq D, Ribaucour F, Wiedig M, Gerbaux C, Leo O, Laurent G, Journe F, Belayew A, Toubeau G: Early expression of the Helicase-Like Transcription Factor (HLTF/SMARCA3) in an experimental model of estrogen-induced renal carcinogenesis. Mol Cancer. 2006, 5: 23- 10.1186/1476-4598-5-23PubMedCentralPubMed
110.
Bultman S, Gebuhr T, Yee D, La Mantia C, Nicholson J, Gilliam A, Randazzo F, Metzger D, Chambon P, Crabtree G, Magnuson T: A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol Cell. 2000, 6 (6): 1287-1295. 10.1016/S1097-2765(00)00127-1PubMed
111.
Roberts CW, Orkin SH: The SWI/SNF complex--chromatin and cancer. Nat Rev Cancer. 2004, 4 (2): 133-142.PubMed
112.
Gibbons RJ: Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet. 2005, 14 Spec No 1: R85-92. 10.1093/hmg/ddi106PubMed
113.
Kouzarides T: Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev. 1999, 9 (1): 40-48. 10.1016/S0959-437X(99)80006-9PubMed
114.
Lehrmann H, Pritchard LL, Harel-Bellan A: Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res. 2002, 86: 41-65.PubMed
115.
Linggi BE, Brandt SJ, Sun ZW, Hiebert SW: Translating the histone code into leukemia. J Cell Biochem. 2005, 96 (5): 938-950. 10.1002/jcb.20604PubMed
116.
Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Cetina L, Candelaria M, Cantu D, Gonzalez-Fierro A, Garcia-Lopez P, Zambrano P, Perez-Plasencia C, Cabrera G, Trejo-Becerril C, Angeles E, Duenas-Gonzalez A: Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer. 2005, 4 (1): 22- 10.1186/1476-4598-4-22PubMedCentralPubMed
117.
Lin RJ, Egan DA, Evans RM: Molecular genetics of acute promyelocytic leukemia. Trends Genet. 1999, 15 (5): 179-184. 10.1016/S0168-9525(99)01710-2PubMed
118.
Hiebert SW, Downing JR, Lenny N, Meyers S: Transcriptional regulation by the t(8;21) fusion protein, AML-1/ETO. Curr Top Microbiol Immunol. 1996, 211: 253-258.PubMed
119.
Di Croce L: Chromatin modifying activity of leukaemia associated fusion proteins. Hum Mol Genet. 2005, 14 Spec No 1: R77-84. 10.1093/hmg/ddi109PubMed
120.
Plass C, Soloway PD: DNA methylation, imprinting and cancer. Eur J Hum Genet. 2002, 10 (1): 6-16. 10.1038/sj.ejhg.5200768PubMed
121.
Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene. 2002, 21 (35): 5400-5413. 10.1038/sj.onc.1205651PubMed
122.
Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002, 3 (6): 415-428.PubMed
123.
Tryndyak VP, Kovalchuk O, Pogribny IP: Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol Ther. 2006, 5 (1): 65-70.PubMed
124.
Tryndyak V, Kovalchuk O, Pogribny IP: Identification of differentially methylated sites within unmethylated DNA domains in normal and cancer cells. Anal Biochem. 2006, 356 (2): 202-207. 10.1016/j.ab.2006.05.019PubMed
125.
126.
Narayan G, Goparaju C, Arias-Pulido H, Kaufmann AM, Schneider A, Durst M, Mansukhani M, Pothuri B, Murty VV: Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer. 2006, 5: 16- 10.1186/1476-4598-5-16PubMedCentralPubMed
127.
Baylin SB, Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000, 16 (4): 168-174. 10.1016/S0168-9525(99)01971-XPubMed
128.
Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, Shi H, Ng SW, Yan PS, Nephew KP, Brown R, Huang TH: Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res. 2002, 8 (7): 2246-2252.PubMed
129.
Lyko F, Stach D, Brenner A, Stilgenbauer S, Dohner H, Wirtz M, Wiessler M, Schmitz OJ: Quantitative analysis of DNA methylation in chronic lymphocytic leukemia patients. Electrophoresis. 2004, 25 (10-11): 1530-1535. 10.1002/elps.200305830PubMed
130.
Teodoridis JM, Strathdee G, Brown R: Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat. 2004, 7 (4-5): 267-278. 10.1016/j.drup.2004.06.005PubMed
131.
Omenn GS: Strategies for plasma proteomic profiling of cancers. Proteomics. 2006, 6 (20): 5662-5673. 10.1002/pmic.200600331PubMed
132.
Peters AH, O'Carroll D, Scherthan H, Mechtler K, Sauer S, Schofer C, Weipoltshammer K, Pagani M, Lachner M, Kohlmaier A, Opravil S, Doyle M, Sibilia M, Jenuwein T: Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell. 2001, 107 (3): 323-337. 10.1016/S0092-8674(01)00542-6PubMed
133.
Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, Nakamura Y: SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004, 6 (8): 731-740. 10.1038/ncb1151PubMed
134.
Tsuge M, Hamamoto R, Silva FP, Ohnishi Y, Chayama K, Kamatani N, Furukawa Y, Nakamura Y: A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. Nat Genet. 2005, 37 (10): 1104-1107. 10.1038/ng1638PubMed
135.
Frank B, Hemminki K, Wappenschmidt B, Klaes R, Meindl A, Schmutzler RK, Bugert P, Untch M, Bartram CR, Burwinkel B: Variable number of tandem repeats polymorphism in the SMYD3 promoter region and the risk of familial breast cancer. Int J Cancer. 2006, 118 (11): 2917-2918. 10.1002/ijc.21696PubMed
136.
Xu JY, Chen LB, Xu JY, Yang Z, Xu RH, Wei HY: [Experimental research of therapeutic effect on hepatocellular carcinoma of targeting SMYD3 gene inhibition by RNA interference]. Zhonghua Wai Ke Za Zhi. 2006, 44 (7): 481-484.PubMed
137.
Xu JY, Chen LB, Xu JY, Yang Z, Wei HY, Xu RH: [Suppression of SMYD3 expression in HepG2 cell by shRNA interference]. Zhonghua Gan Zang Bing Za Zhi. 2006, 14 (2): 105-108.PubMed
138.
Xu JY, Chen LB, Xu JY, Yang Z, Wei HY, Xu RH: [Inhibition of SMYD3 gene expression by RNA interference induces apoptosis in human hepatocellular carcinoma cell line HepG2]. Ai Zheng. 2006, 25 (5): 526-532.PubMed
139.
Wang H, Cao R, Xia L, Erdjument-Bromage H, Borchers C, Tempst P, Zhang Y: Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol Cell. 2001, 8 (6): 1207-1217. 10.1016/S1097-2765(01)00405-1PubMed
140.
Nishioka K, Chuikov S, Sarma K, Erdjument-Bromage H, Allis CD, Tempst P, Reinberg D: Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev. 2002, 16 (4): 479-489. 10.1101/gad.967202PubMedCentralPubMed
141.
Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempst P, Prives C, Gamblin SJ, Barlev NA, Reinberg D: Regulation of p53 activity through lysine methylation. Nature. 2004, 432 (7015): 353-360. 10.1038/nature03117PubMed
142.
Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T, Berger SL: Repression of p53 activity by Smyd2-mediated methylation. Nature. 2006, In press:
143.
Mattick JS, Makunin IV: Small regulatory RNAs in mammals. Hum Mol Genet. 2005, 14 Spec No 1: R121-32. 10.1093/hmg/ddi101PubMed
144.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature. 2005, 435 (7043): 834-838. 10.1038/nature03702PubMed
145.
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65 (16): 7065-7070. 10.1158/0008-5472.CAN-05-1783PubMed
146.
Calin GA, Garzon R, Cimmino A, Fabbri M, Croce CM: MicroRNAs and leukemias: how strong is the connection?. Leuk Res. 2006, 30 (6): 653-655. 10.1016/j.leukres.2005.10.017PubMed
147.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006, 103 (7): 2257-2261. 10.1073/pnas.0510565103PubMedCentralPubMed
148.
Horsthemke B: Epimutations in human disease. Curr Top Microbiol Immunol. 2006, 310: 45-59.PubMed
149.
Brown R, Strathdee G: Epigenomics and epigenetic therapy of cancer. Trends Mol Med. 2002, 8 (4 Suppl): S43-8. 10.1016/S1471-4914(02)02314-6PubMed
150.
Lyko F, Brown R: DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst. 2005, 97 (20): 1498-1506.PubMed
151.
Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006, 6 (1): 38-51. 10.1038/nrc1779PubMed
152.
Lind GE, Thorstensen L, Lovig T, Meling GI, Hamelin R, Rognum TO, Esteller M, Lothe RA: A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer. 2004, 3: 28- 10.1186/1476-4598-3-28PubMedCentralPubMed
153.
Claus R, Fliegauf M, Stock M, Duque J, Kolanczyk M, Lubbert M: Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression. J Leukoc Biol. 2006.
154.
Claus R, Almstedt M, Lubbert M: Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents. Semin Oncol. 2005, 32 (5): 511-520. 10.1053/j.seminoncol.2005.07.024PubMed
155.
Alao JP, Stavropoulou AV, Lam EW, Coombes RC, Vigushin DM: Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer. 2006, 5: 8- 10.1186/1476-4598-5-8PubMedCentralPubMed
Metadata
Title
Epigenetic aberrations and cancer
Authors
Miryam Ducasse
Mark A Brown
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2006
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-5-60

Other articles of this Issue 1/2006

Molecular Cancer 1/2006 Go to the issue

Research

Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression

Research

Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest

Research

Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling

Research

Tumor cell invasion of collagen matrices requires coordinate lipid agonist-induced G-protein and membrane-type matrix metalloproteinase-1-dependent signaling

Review

Application of cytology and molecular biology in diagnosing premalignant or malignant oral lesions

Research

Altered Ca2+ homeostasis in polymorphonuclear leukocytes from chronic myeloid leukaemia patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits